Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Steinhubl SR, et al. Among authors: lincoff am. Circulation. 2001 May 29;103(21):2572-8. doi: 10.1161/01.cir.103.21.2572. Circulation. 2001. PMID: 11382726 Clinical Trial.
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: lincoff am. Eur Heart J. 2002 Feb;23(3):239-46. doi: 10.1053/euhj.2001.2736. Eur Heart J. 2002. PMID: 11792139 Clinical Trial.
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Lincoff AM, et al. Am Heart J. 2002 May;143(5):847-53. doi: 10.1067/mhj.2002.122173. Am Heart J. 2002. PMID: 12040347 Clinical Trial.
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM; Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. Bhatt DL, et al. Among authors: lincoff am. J Am Coll Cardiol. 2003 Jan 1;41(1):20-5. doi: 10.1016/s0735-1097(02)02631-1. J Am Coll Cardiol. 2003. PMID: 12570939 Free article. Clinical Trial.
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ; SYNERGY Library. Petersen JL, et al. Among authors: lincoff am. Am Heart J. 2004 Aug;148(2):269-76. doi: 10.1016/j.ahj.2004.03.022. Am Heart J. 2004. PMID: 15308996 Clinical Trial.
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, Van de Werf F, Simes J, White HD, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Labinaz M, et al. Among authors: lincoff am. Eur Heart J. 2005 Jan;26(2):128-36. doi: 10.1093/eurheartj/ehi061. Epub 2004 Dec 9. Eur Heart J. 2005. PMID: 15618068
427 results